🔗 Share this article

Given that America continues making sweeping revisions to its immunization guidelines, one figure has emerged unexpectedly: Høeg, a US-based sports physician and epidemiologist who initially gained attention by questioning COVID-19 vaccines during the pandemic and has focused upon possible deaths following COVID-19 vaccination in her recent position at the FDA.

Proposed Changes to Childhood Vaccine Schedule

Public health authorities were set to reveal sweeping revisions to the pediatric immunization program recently, aligning the US with the Danish immunization schedule, it is understood – a major change that would place the US at odds with much of the world with little proof for public health gain. The planned update has been delayed until the new year.

Rather than the director of the vaccine center, Tracy Beth Høeg is scheduled to present at the meeting. She was recently named acting director of the FDA’s drug evaluation center, the fifth appointee to run the center this year.

A New Direction at the Regulatory Body

The acting appointment might represent a tighter collaboration between the pharmaceutical and biologics centers as Dr. Høeg and Dr. Prasad solidify control at the FDA – and it points to a renewed priority upon rolling back previously authorized vaccines at the FDA.

Dr. Høeg has repeatedly called for halting specific childhood vaccine recommendations in the US in order to be more similar to Denmark, a society with comprehensive healthcare and a number of inhabitants about the population of the state of Wisconsin.

In her initial comments, she has kept her attention on vaccination policy – typically the responsibility of Prasad, director of the FDA’s CBER – as opposed to pharmaceutical oversight.

Doubts Over Expertise

Høeg has no apparent track record in pharmaceutical research, oversight or leadership, which has been customary for past heads of the CBER. She has served at the FDA as a top consultant to the FDA chief and CBER since spring.

“It seems she lacks to have any of the qualifications” for overseeing the drug-regulation department, stated Jonathan Howard. “She lacks experience running a clinical trial. She has no expertise in managing a large organization. She is not an expert in pharmaceutical oversight.”

Past heads of CBER would “be deeply familiar with regulatory frameworks and the underlying principles of drug development”, said a former acting FDA commissioner. “Frankly, she lacks the type of experience that former directors who headed CBER have had.”

The drug center has an immense workload at the FDA, the former commissioner stated.

“Everybody just zeroes in on the innovative therapies, but the generic drug division clears numerous generic drugs. There’s a biosimilars division, over-the-counter program and so forth, and every single one have to be supervised,” Woodcock explained. “The responsibility you neglect, that is the part that I always told people is going to bite you.”

There is also, a substantial management element to the role, which oversees over 5,000 employees. “It’s a massive administrative position, if you execute it properly,” the former official said.

Response and Disputed Programs

In response to questions about Høeg’s qualifications and whether this assignment signifies increased cooperation among regulatory chiefs on immunizations, a press secretary said that the “inquiries rely on inaccurate assumptions”.

“Her resume is consistent with the duties of her position,” the official stated, noting the time Høeg spent guiding the FDA commissioner on “medication safety and approval science, including computerized risk analysis and shot safety tracking”.

In her interim role, Dr. Høeg takes over the commissioner’s recently launched priority voucher program, a disputed one-day medication authorization process that allegedly concerned her former heads. “By what process are these therapies being selected for this fast-track system? Who takes the calls?” Howard said. “There’s a lot of lack of transparency happening at the agency right now.”

In general, he said, “the agency looks to be trending towards laxer rules of most medications, with the exception of immunizations.”

Public History on Vaccines

Concerning immunizations, Dr. Høeg has a more established, if concerning, track record, critics said. She published a analysis using unverified volunteer-provided data to estimate the incidence of myocarditis following Covid immunization. She consulted for the Florida surgeon general Dr. Joseph Ladapo, who reportedly have changed statistics to suggest COVID-19 vaccines are riskier than they are.

Among her “wish list” for the new government included altering guidelines for new vaccines and ending “non-essential” vaccines, she stated after the election on a podcast. At the agency, Dr. Høeg has allegedly suggested preventing young men from receiving COVID-19 vaccines.

“She’s an thorough dogmatist who starts off with her preconceived notions and works backwards to retrofit the science in a highly disingenuous, fraudulent manner,” Dr. Howard said.

Gaining Influence and a “Campaign of Retribution”

Høeg joined fellow dissenters, {like|